In the intricate landscape of (bio)pharmaceutical development, international trade compliance emerges as a critical factor influencing the success of therapeutic products and medical devices. The collaboration with a full-service Contract Development and Manufacturing Organization (CDMO) takes center stage, offering expertise that spans the entire lifecycle of a drug development project. From addressing early-phase challenges to ensuring seamless tech transfers and meeting stringent regulatory guidelines, a reliable CDMO plays a pivotal role in navigating the complexities of global compliance measures.
The increasing global trade of pharmaceutical products underscores the need for (bio)pharmaceutical companies to be well-versed in international trade requirements. This white paper explores the impact of factors like the COVID-19 pandemic on global trade, emphasizing the importance of a robust international trade compliance program. Beyond mitigating risks of governmental investigations and penalties, a well-established compliance program becomes a strategic advantage, fostering a comprehensive supply chain and cost management for drugs and medical devices. The collaboration with a CDMO equipped with a dedicated trade compliance team becomes a decisive factor in ensuring consistent planning, accurate cost estimation, and enhanced delivery timelines for materials shipped across borders.
Download our white paper to gain insights on:
- Strategies to mitigate the risks of governmental investigations and penalties through the establishment of a robust international trade compliance program.
- The increasing importance of (bio)pharmaceutical companies being well-versed in international trade requirements and the impact of global events, such as the COVID-19 pandemic, on trade dynamics.
- The pivotal role of a full-service Contract Development and Manufacturing Organization (CDMO) in overcoming early-phase challenges and ensuring seamless tech transfers for (bio)pharmaceutical development.
- The strategic advantage offered by a well-established compliance program in fostering efficient supply chain management and cost control for drugs and medical devices.
More from Curia
Often, aggressive timelines are imposed on development projects with the aim of getting to First-in-Human trials as soon as possible. However, formulation development can be met with many challenges as biologics are often sensitive molecules with a v...